Claritin label change
This article was originally published in The Tan Sheet
FDA approves Schering-Plough's request to add the descriptor "Indoor & Outdoor Allergies" to the principal display panel of 10- and 30-count carton labels of Claritin Liqui-Gels (loratadine 10 mg), according to an April 6 letter. The change could extend the medicine's benefits beyond seasonal allergies. FDA approved a similar change to Claritin packaging in 2008 (1"The Tan Sheet" Jan. 28, 2008, In Brief)
You may also be interested in...
FDA will allow Schering-Plough to communicate on its product label that Claritin relieves both indoor and outdoor allergies, potentially extending the OTC non-drowsy allergy medicine's benefits beyond seasonal allergy treatment. Previously, labels could only state that Claritin relieves outdoor allergies, S-P says Jan. 22...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.